Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer

Toronto, Ontario – September 19, 2017

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human pharyngeal carcinoma cell line, FaDu.

In 2016, according to the American Society of Clinical Oncology (“ASCO”), an estimated 49,670 adults (35,720 men and 13,950 women) in the United States will be diagnosed with oral and oropharyngeal cancer. Rates of these cancers are more than twice as high in men, as in women. Cancer of the oral cavity is the ninth most common cancer among men. The average age of diagnosis is 62.

The overall 5-year survival rate for people with oral or oropharyngeal cancer is 64%.

It is estimated that 9,700 deaths (7,000 men and 2,700 women) from these 2 diseases will occur this year.

In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that a human pharyngeal carcinoma cell line (FaDu) was 98% destroyed, at an extremely low dose of TLD-1433 (0.2 micromolar), when activated by green laser light (530 nm, 90 J/cm2) and 98% destroyed, at a low dose of TLD-1433 (25 micromolar), when activated by red laser light (625 nm, 90 J/cm2).

The ability to activate TLD-1433 at both green and red laser wavelengths allows the PDC to be activated at various tissue depths corresponding to the progression of the disease.

The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, when activated by green laser light, and low, when activated by red laser light, supporting a high safety margin in the destruction of human pharyngeal carcinoma cells.


Dr. Kaspler stated that, “The research data strongly supports that TLD-1433 would be effective in the destruction of human pharyngeal carcinoma cells with a high safety margin. I look forward to continuing my research in this promising new cancer indication.”

Dr. Mandel stated that, “TLD-1433 continues to advance in the destruction of new oncology targets, demonstrating high efficacy in the destruction of numerous cancers preclinically. We have strong preclinical data supporting the use of Rutherrin® (TLD-1433 + transferrin) in the destruction of glioblastoma brain cancer and lung cancer and now TLD-1433 on its own in the destruction of cervical and pharyngeal cancer.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “The Theralase licenced PDCs have proven to be very strong anti-cancer drugs in initial clinical studies for NMIBC and preclinically for glioblastoma, lung, cervical and now pharyngeal cancer. We look forward to successfully expanding the clinical application of our platform of PDCs, and the laser light systems that activate them, through Phase Ib clinical studies, as we expand into these new oncological targets.”


About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Corporation”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at and

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.


For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225